A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy

Blood

Volumn 119, Issue 8, 2012, Pages

  Canavan, James B ^a   Afzali, Behdad ^a   Scottà, Cristiano ^a   Fazekasova, Henrieta ^a   Edozie, Francis C ^a   Macdonald, Thomas T ^b   Hernandez Fuentes, Maria P ^a   Lombardi, Giovanna ^a   Lord, Graham M ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD69 ANTIGEN;

ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL ASSAY; CELL ISOLATION; CELL KINETICS; CELL THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIAGNOSTIC TEST; EX VIVO STUDY; FLOW CYTOMETRY; GOLD STANDARD; HUMAN; HUMAN CELL; INFORMATION PROCESSING; INHIBITION KINETICS; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL;

EID: 84857565392     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-380048     Document Type: Article

References (38)

1. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol. 2007;148(1):32-46. (Pubitemid 46365005)
2. Atalar K, Afzali B, Lord G, Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr Opin Organ Transplant. 2009;14(1):23-29.
3. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev. 2006;212:203-216. (Pubitemid 44116710)
4. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199(7):971-979. (Pubitemid 38481088)
5. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;54(1):92-99. (Pubitemid 40105099)
6. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174(1):164-173. (Pubitemid 40007402)
7. Chatila TA, Blaeser F, Ho N, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome. J Clin Invest. 2000;106(12):R75-R81. (Pubitemid 32038594)
8. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. 2007;178(4):2579-2588. (Pubitemid 46233461)
9. Ferber IA, Brocke S, Taylor-Edwards C, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol. 1996;156(1):5-7.
10. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233-240. (Pubitemid 40189432)
11. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 1995;16(1):34-38.
12. Lubberts E, Joosten LAB, van de Loo FAJ, Schwarzenberger P, Kolls J, van den Berg WB. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res. 2002;51(2):102-104. (Pubitemid 34183634)
13. Gill JS. Cardiovascular disease in transplant recipients: current and future treatment strategies. Clin J Am Soc Nephrol. 2008;3(suppl 2):S29-S37.
14. Regazzi MB, Alessiani M, Rinaldi M. New strategies in immunosuppression. Transplant Proc. 2005;37(6):2675-2678. (Pubitemid 41354707)
15. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis. 2005;18(4):342-345. (Pubitemid 41017640)
16. Sagoo P, Lombardi G, Lechler RI. Regulatory T cells as therapeutic cells. Curr Opin Organ Transplant. 2008;13(6):645-653.
17. Trzonkowski P, Bieniaszewska M, Juoecińska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol. 2009;133(1):22- 26.
18. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One. 2009;4(6):e5994.
19. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921-3928.
20. Mardiney M 3rd, Brown MR, Fleisher TA. Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigeninduced proliferative capacity in normals. Cytometry. 1996;26(4):305-310.
21. Kawabe T, Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity. 1994;1(3):167-178.
22. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2-17. (Pubitemid 30046812)
23. Armitage RJ, Fanslow WC, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature. 1992;357(6373):80-82.
24. Yellin MJ, Sippel K, Inghirami G, et al. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/ CD40-L: potential role in regulating helper effector function. J Immunol. 1994;152(2):598-608. (Pubitemid 24072963)
25. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med. 2005;11(10):1113-1117. (Pubitemid 41486835)
26. Frentsch M, Arbach O, Kirchhoff D, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med. 2005;11(10):1118-1124. (Pubitemid 41486836)
27. Wells AD, Gudmundsdottir H, Turka LA. After the fate of individual T cells throughout activation and clonal expansion: signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest. 1997;100(12):3173-3183. (Pubitemid 28022856)
28. Battaglia M, Stabilini A, Migliavacca B, Horejs- Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12):8338-8347. (Pubitemid 44893795)
29. Tresoldi E, Dell'albani I, Stabilini A, et al. Stability of human rapamycin-expanded CD4+ CD25+ T regulatory cells. Haematologica. 2011;96(9):1357-1365.
30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310. (Pubitemid 16134762)
31. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.
32. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061-1070.
33. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation. 2010;90(12):1321-1327.
34. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3(83):83ra42.
35. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med. 2010;16(7):809-813.
36. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ. IFN-gamma production by alloantigen- reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med. 2005;201(12):1925-1935. (Pubitemid 41002929)
37. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10(6):595-602.
38. Evans HG, Suddason T, Jackson I, Taams LS, Lord GM. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci U S A. 2007;104(43):17034- 17039.